Effects of highly active antiretroviral therapy on HIV-1-associated oral complications

Current HIV Research

Volumn 5, Issue 3, 2007, Pages 281-292

  Parveen, Zahida ^a   Acheampong, Edward ^a   Pomerantz, Roger J ^b   Jacobson, Jeffrey M ^c   Wigdahl, Brian ^c   Mukhtar, Muhammad ^c,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Tibotec Inc   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d PMAS ARID AGRICULTURE UNIVERSITY   (Pakistan)

Author keywords

AIDS; Antimicrobial; Human Papillomavirus; Non nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Oral cavity; Salivery glands

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; ENFUVIRTIDE; FLUCONAZOLE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; THALIDOMIDE; ZALCITABINE; ZIDOVUDINE;

AGE DISTRIBUTION; APHTHOUS ULCER; BACTERIAL INFECTION; DISEASE SEVERITY; EPITHELIUM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; MOUTH DISEASE; MOUTH INFECTION; MOUTH MUCOSA; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PROGNOSIS; RESERVOIR; REVIEW; SALIVA LEVEL; SALIVARY GLAND DISEASE; SIDE EFFECT; THERAPY EFFECT; THRUSH; VERRUCA VULGARIS; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REACTIVATION; WART VIRUS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; HIV INFECTIONS; HIV-1; HUMANS; MOUTH DISEASES;

EID: 34249075786     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207780636533     Document Type: Review

References (182)

1. Acheampong EA, Parveen Z, Muthoga LW, Wasmuth-Peroud V, Kalayeh M, Bashir A, Diecidue R, Mukhtar M, Pomerantz RJ. (2005). Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytcs. Journal of Virology. 79:8440-8453.
2. Agbelusi GA, Wright AA. (2005). Oral lesions as indicators of HIV infection among routine dental patients in Lagos, Nigeria. Oral Diseases. 11:370-373.
3. Allaker RP, Grosvenor PW, McAnemey DC, Sheehan BE, Srikanta BH, Pell K, Kapas S. (2006). Mechanisms of adrenomodullin antimicrobial action. Peptides. 27:661-666.
4. Allaker RP, Kapas S. (2003). Adrenomedullin and mucosal defence: interaction between host and microorganism. Regulatory Peptides. 112:147-152.
5. Amayo EO, Riyat MS, Okelo GB, Adam AM, Toroitich K. (1993). Disseminated histoplasmosis in a patient with acquired immunodeficiency syndrome (AIDS): a case report. East African Medical Journal. 70:61-62.
6. Arendorf TM, Bredekamp B, Cloete CA, Sauer G. (1998). Oral manifestations of HIV infection in 600 South African patients. Journal of Oral Pathology and Medicine. 27:176-179.
7. Baba TW, Trichel AM, An L, Liska V, Martin LN, Murphey-Corb M, Ruprecht RM. (1996). Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science. 272:1486-1489.
8. Bagasra O, Bachman SE, Jew L, Tawadros R, Cater J, Boden G, Ryan I, Pomerantz RJ. (1996). Increased human immunodeficiency virus type 1 replication in human peripheral blood mononuclear cells induced by ethanol: potential immunopathogenic mechanisms. The Journal of Infectious Diseases. 173:550-558.
9. Baqui AA, Meiller TF, Falkler WA, Jr. (1999). Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients. Clinical and Diagnostic Laboratory Immunology. 6:808-811.
10. Baron S, Poast J, Cloyd MW. (1999). Why is HTV rarely transmitted by oral ecretions? Saliva can disrupt orally shed, infected leukocytes. Archives of Internal Medicine. 159:303-310.
11. Becquart P, Gresenguet G, Hocini H, Kazatchkine MD, Belec L. (1999). Secretory leukocyte protease inhibitor in colostrum and breast milk is not a major determinant of the protection of early postnatal transmission of HIV. AIDS. 13:2599-2602.
12. Bergey EJ, Cho MI, Blumberg BM, Hammarskjold ML, Rekosh D, Epstein LG, Levine MJ. (1994). Interaction of HIV-1 and human salivary mucins. Journal of Acquired Immune Deficiency Syndromes. 7:995-1002.
13. Blanco MT, Hurtado C, Perez-Giraldo C, Moran FJ, Gonzalez-Velasco C, Gomez-Garcia AC. (2003). Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases. Medical Mycology. 41:167-170.
14. Bolscher JG, Nazmi Y, Ran LJ, van Engelenburg FA, Schuitemaker H, Veerman EC, Nieuw Amerongen AV. (2002). Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. European Journal of Oral Sciences. 110:149-156.
15. Brawner DL, Cutler JE. (1989). Oral Candida albicans isolates from non-hospitalized normal carriers, immunocompetent hospitalized patients, immunocompromised patients with or without acquired immunodeficiency syndrome. Journal of Clinical Microbiology. 27:1335-1341.
16. Caddy B. (1984). Saliva as a specimen for drug analysis. In R.C. Baselt (Ed.) Advances in analytical toxicology, Foster City: Biomedical Publications. 1:198-254.
17. Cameron JE, Mercante D, O'Brien M, Gaffga AM, Leigh JE, Fidel PL, Jr., Hagensee ME. (2005). The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus-seropositive adults. Sexually Transmitted Diseases. 32:703-709.
18. Campo J, Perea MA, del Romero J, Cano J, Hernando V, Bascones A. (2006). Oral transmission of HIV, reality or fiction? An update. Oral Diseases. 12:219-228.
19. Casper C, Redman M, Huang ML, Pauk J, Lampinen TM, Hawes SE, Critchlow CW, Morrow RA, Corey L, Kiviat N, Wald A. (2004). HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. Journal of Acquired Immune Deficiency Syndromes. 35:233-238.
20. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. (1999). In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. The Journal of Infectious Diseases. 180:448-453.
21. Cauda R, Tacconelli E, Tumbarello M, Morace G, De Bernardis F, Torosantucci A, Cassone A. (1999). Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. Journal of Acquired Immune Deficiency Syndromes. 21:20-25.
22. Chang TL, Vargas J, Jr., DelPortillo A, Klotman ME. (2005). Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. Journal of Clinical Investigation. 115:765-773.
23. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. (1994). Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1865-1869.
24. Chen H, Zha J, Gowans RE, Camargo P, Nishitani J, McQuirter JL, Cole SW, Zack JA, Liu X. (2004). Alcohol enhances HIV type 1 infection in normal human oral keratinocytes by up-regulating cell-surface CXCR4 coreceptor. AIDS Research and Human Retroviruses. 20:513-519.
25. Chin-Hong PV, Palefsky JM. (2005). Human papillomavirus anogenital disease in HIV-infected individuals. Dermatologic Therapy. 18:67-76.
26. Chou LL, Epstein J, Cassol SA, West DM, He W, Firth JD. (2000). Oral mucosal Langerhans' cells as target, effector and vector in HIV infection. Journal of Oral Pathology and Medicine. 29:394-402.
27. Coogan MM, Greenspan J, Challacombe SJ. (2005). Oral lesions in infection with human immunodeficiency virus. Bulletin of the World Health Organization. 83:700-706.
28. Crombie R. (2000). Mechanism of thrombospondin-1 anti-HIV-1 activity. AIDS Patient Care and STDs. 14:211-214.
29. Dale BA, Fredericks LP. (2005). Antimicrobial pcptides in the oral environment: expression and function in health and disease. Current Issues in Molecular Biology. 7:119-133.
30. Dale BA, Kimball JR, Krisanaprakomkit S, Roberts F, Robinovitch M, O'Neal R, Valore EV, Ganz T, Anderson GM, Weinberg A. (2001). Localized antimicrobial peptide expression in human gingiva. Journal of Periodental Research. 36:285-294.
31. De Bernardis F, Boccanera M, Rainaldi L, Guerra CE, Quinti I, Cassone A. (1992). The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects. European Journal of Epidemiology. 8:362-367.
32. De Bernardis F, Chiani P, Ciccozzi M, Pellegrini G, Ceddia T, D'Offizzi G, Quinti I, Sullivan PA, Cassone A. (1996). Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infection and Immunity. 64:466-471.
33. De Bernardis F, Tacconelli E, Mondello F, Cataldo A, Arancia S, Cauda R, Cassone A. (2004). Anti-retroviral therapy with protease, inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. FEMS Immunology and Medical Microbiology. 41:27-34.
34. Dias EP, Israel MS, Silva Junior A, Maciel VA, Gagliardi JP, Oliveira RH. (2006). Prevalence of oral hairy leukoplakia in 120 pediatric patients infected with HIV-1. Pesqui Odontol Bras. 20:103-107.
35. Dodd CL, Greenspan D, Katz MH, Westenhouse JL, Feigal DW, Greenspan JS. (1991). Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. AIDS. 5:1339-1343.
36. Dupont B, Drouhet E. (1988). Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. Journal of Medical and Veterinary Mycology. 26:67-71.
37. Emerson KA, Venugopal N, Huang CB, Ebersole JL. (2005). Oral bacterial reactivation of HIV in macrophages. IADR/AADR/CADR 83rd General Session (March 9-12, 2005) Abstract 1057.
38. Eyeson JD, Tenant-Flowers M, Cooper DJ, Johnson NW, Warnakulasuriya KA. (2002). Oral manifestations of an HIV positive cohort in the era of highly active anti-retroviral therapy (HAART) in South London. Journal of Oral Pathology and Medicine. 31:169-174.
39. Faruque S, Edlin BR, McCoy CB, Word CO, Larsen SA, Schmid DS, Von Bargen JC, Serrano Y. (1996). Crack cocaine smoking and oral sores in three inner-city neighborhoods. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 13:87-92.
40. Fauci AS. (2006). Twenty-five years of HIV/AIDS. Science. 313:409.
41. Feng Z, Dubyak GR, Lederman MM, Weinberg A. (2006). Cutting edge: human beta defensin 3-a novel antagonist of the HIV-1 coreceptor CXCR4. The Journal of Immunology. 177:782-786.
42. Franker CK, Lucartorto FM, Johnson BS, Jacobson JJ. (1990). Characterization of the mycoflora from oral mucosal surfaces of some HIV-infected patients. Oral Surgery, Oral Medicine, Oral Pathology. 69:683-687.
43. Freel SA, Williams JM, Nelson JA, Patton LL, Fiscus SA, Swanstrom R, Shugars DC. (2001). Characterization of human immunodeficiency virus type 1 in saliva and blood plasma by V3-specific heteroduplex tracking assay and genotype analyses. Journal of Virology. 75:4936-4940.
44. Gandhi M, Koelle DM, Ameli N, Bacchetti P, Greenspan JS, Navazesh M, Anastos K, Greenblatt RM. (2004). Prevalence of human herpesvirus-8 salivary shedding in HIV increases with CD4 count. Journal of Dental Research. 83:639-643.
45. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR, 3rd. (2006). Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA. 296:292-300.
46. Goto Y, Yeh CK, Notkins AL, Prabhakar BS. (1991). Detection of proviral sequences in saliva of patients infected with human immunodeficiency virus type 1. AIDS Research and Human Retroviruses. 7:343-347.
47. Gottfredsson M, Cox GM, Indridason OS, de Almeida GM, Heald AE, Perfect JR. (1999). Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. The Journal of Infectious Diseases. 180:534-537.
48. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. (2001). Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 357:1411-1412.
49. Greenspan D, Gange SJ, Phelan JA, Navazesh M, Alves ME, MacPhail LA, Mulligan R, Greenspan JS. (2004). Incidence of oral lesions in HIV-1-infected women: reduction with HAART. Journal of Dental Research. 83:145-150.
50. Greenspan D, Greenspan JS. (1996). HIV-related oral disease. Lancet 348:729-733.
51. Greenspan D, Greenspan JS, Hearst NG, Pan LZ, Conant MA, Abrams DI, Hollander H, Levy JA. (1987). Relation of oral hairy leukoplakia to infection with the human immunodeficiency virus and the risk of developing AIDS. The Journal of Infectious Diseases. 155:475-481.
52. Greenspan D, Komaroff E, Redford M, Phelan JA, Navazesh M, Alves ME, Kamrath H, Mulligan R, Barr CE, Greenspan JS. (2000). Oral mucosal lesions and HIV viral load in the Women's Interagency IRV Study (WIHS). Journal of Acquired Immune Deficiency Syndromes. 25:44-50.
53. Guggenheimer J, Moore PA. (2003). Xerostomia: etiology, recognition and treatment. The Journal of the American Dental Association. 134:61-69; quiz 118-119.
54. Guthmiller JM, Vargas KG, Srikantha R, Schomberg LL, Weistroffer PL, McCray PB, Jr., Tack BF. (2001). Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrobial Agents and Chemotherapy. 45:3216-3219.
55. Hagensee ME, Cameron JE, Leigh JE, Clark RA. (2004). Human papillo-mavirus infection and disease in HIV-infected individuals. The American Journal of the Medical Sciences. 328:57-63.
56. Han Y, Ventura CL, Black KP, Cummins JE, Jr., Hall SD, Jackson S. (2000). Productive human immunodeficiency virus-1 infection of epithelial cell lines of salivary gland origin. Oral Microbiology and Immunology. 15:82-88.
57. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P. (1998). Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell. 95:163-175.
58. Harder J, Bartels J, Christophers E, Schroder JM. (2001). Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic. Journal of Biological Chemistry. 276:5707-5713.
59. Heinic GS, Greenspan D, MacPhail LA, Schiodt M, Miyasaki SH, Kaufman L, Greenspan JS. (1992). Oral Histoplasma capsulatum infection in association with HIV infection: a case report. Journal of Oral Pathology and Medicine. 21:85-89.
60. Hernandez SL, Lopez De Blanc SA, Sambuelli RH, Roland H, Cornelli C, Lattanzi V, Carnelli MA. (2004). Oral histoplasmosis associated with HIV infection: a comparative study. Journal of Oral Pathology and Medicine. 33:445-450.
61. Ho DD, Schooley RT, Rota TR, Kaplan JC, Flynn T, Salahuddin SZ, Gonda MA, Hirsch MS. (1984). HTLV-III in the semen and blood of a healthy homosexual man. Science. 226:451-453.
62. Hritz I, Kuester D, Vieth M, Herszenyi L, Stolte M, Roessner A, Tulassay Z, Wex T, Malfertheiner P. (2006). Secretory leukocyte protease inhibitor expression in various types of gastritis: a specific role of Helicobacter pylori infection. European Journal of Gastroenterology and Hepatology. 18:277-282.
63. Itin PH. (1993). Oral hairy leukoplakia-10 years on. Dermatology. 187:159-163.
64. Jacobson JM, Greenspan IS, Spritzler J, Fox L, Fahey JL, Jackson JB, Chernoff M, Wohl DA, Pulvirenti JJ, Hooton TM, Shikuma C. (2001). Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. The Journal of Infectious Diseases. 183:343-346.
65. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, Wohl DA. (1997). Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. The New England Journal of Medicine. 336:1487-1493.
66. Jacobson JM, Spritzler J, Fox L, Fahey JL, Jackson JB, Chernoff M, Wohl DA, Wu AW, Hooton TM, Sha BE, Shikuma CM, MacPhail LA, Simpson DM, Trapnell CB, Basgoz N. (1999). Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group. The Journal of Infectious Diseases. 180:61-67.
67. Janoff EN, Scamurra RW, Sanneman TC, Eidman K, Thum JR. (1999). Human immunodeficiency virus type 1 and mucosal humoral defense. The Journal of Infectious Diseases. 179(Suppl 3):S475-479.
68. Kazmi SH, Naglik JR, Sweet SP, Evans RW, O'Shea S, Banatvala JE, Challacombe SJ. (2006). Comparison of HIV-1 specific inhibitory activity in saliva and other human mucosal fluids. Clinical and Vaccine Immunology. 13: 1111-1118.
69. Kennedy S, Davis C, Abrams WR, Billings PC, Nagashunmugam T, Friedman H, Malamud D. (1998). Submandibular salivary proteases: lack of a role in anti-HIV activity. Journal of Dental Research. 77:1515-1519.
70. Kerdpon D, Pongsiriwet S, Pangsomboon K, Iamaroon A, Kampoo K, Sretrirutchai S, Geater A, Robison V. (2004). Oral manifestations of HIV infection in relation to clinical and CD4 immunological status in northern and southern Thai patients. Oral Diseases. 10:138-144.
71. Kerr AR, Ship JA. (2003). Management strategies for HIV-associated aphthous stomatitis. American Journal of Clinical Dermatology. 4:669-680.
72. Kim HN, Meier A, Huang ML, Kuntz S, Selke S, Celum C, Corey L, Wald A. (2006). Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. The Journal of Infectious Diseases. 194:420-427.
73. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. (2002). Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clinical. Infectious Diseases. 34:641-648.
74. Klotman ME, Chang TL. (2006). Defensins in innate antiviral immunity. Nature Reviews Immunology. 6:447-456.
75. Koelle DM, Huang ML, Chandran B, Vieira J, Piepkorn M, Corey L. (1997). Frequent detection of Kaposi's sarcoma-associated herpesvinis (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. The Journal of Infectious Diseases. 176:94-102.
76. Krisanaprakornkit S, Weinberg A, Perez CN, Dale BA. (1998). Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infection and Immunity. 66:4222-4228.
77. Lafferty WE, Hughes JP, Handsfield HH. (1997). Sexually transmitted diseases in men who have sex with men. Acquisition of gonorrhea and non-gonococcal urethritis by fellatio and implications for STD/HIV prevention. Sexually Transmitted Diseases. 24:272-278.
78. Leibovitz E, Rigaud M, Chandwani S, Kaul A, Greco MA, Pollack H, Lawrence R, Di John D, Hanna B, Krasinski K, and et al. (1991). Disseminated fungal infections in children infected with human immunodeficiency virus. The Pediatric Infectious Disease Journal. 10:888-894.
79. Levy JA, Greenspan D. (1988). HIV in saliva. Lancet. 2:1248.
80. Lewandowski D, Marquis M, Aumont F, Lussier-Morin AC, Raymond M, Senechal S, Hanna Z, Jolicoeur P, de Repentigny L. (2006). Altered CD4+ T cell phenotype and function determine the susceptibility to mucosal candidiasis in transgenic mice expressing HIV-1. Journal of Immunology. 177:479-491.
81. Lifson AR, O'Malley PM, Hessol NA, Buchbinder SP, Cannon L, Rutherford GW. (1990). HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counseling concerning safe sexual practices. American Journal of Public Health. 80:1509-1511.
82. Lin AL, Johnson DA, Patterson TF, Wu Y, Lu DL, Shi Q, Yen CK. (2001). Salivary anticandidal activity and saliva composition in an HIV-infected cohort. Oral Microbiology and Immunology. 16:270-278.
83. Lin AL, Johnson DA, Sims CA, Stephan KT, Yeh CK. (2006). Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, Endodontology. 102:318-324.
84. Lin AL, Johnson DA, Stephan KT, Yeh CK. (2003). Alteration in salivary function in early HIV infection. Journal of Dental Research. 82:719-724.
85. Lin AL, Johnson DA, Stephan KT, Yeh CK. (2004). Salivary secretory leukocyte protease inhibitor increases in HIV infection. Journal of Oral Pathology and Medicine. 33:410-416.
86. Ling PD, Vilchez RA, Keitel WA, Poston DG, Peng RS, White ZS, Visnegarwala F, Lewis DE, Butel JS. (2003). Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clinical Infectious Diseases. 37:1244-1249.
87. Liu X, Zha J, Chen H, Nishitani J, Camargo P, Cole SW, Zack JA. (2003). Human immunodeficiency virus type 1 infection and replication in normal human oral keratinocytes. Journal of Virology. 77:3470-3476.
88. Liuzzi G, Chirianni A, Clementi M, Bagnarelli P, Valenza A, Cataldo PT, Piazza M. (1996). Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS. 10:F51-56.
89. Liuzzi G, Chirianni A, Clementi M, Zaccarelli M, Antinori A, Piazza M. (2002). Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen. AIDS. 16:503-504.
90. Lucht E, Brytting M, Bjerregaard L, Julander I, Linde A. (1998). Shedding of cytomegalovirus and herpesviruses 6, 7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls. Clinical Infectious Diseases. 27:137-141.
91. Macluskey M, Baillie R, Morrow H, Schor SL, Schor AM. (2006). Extraction of RNA from archival tissues and measurement of thrombospondin-1 mRNA in normal, dysplastic, and malignant oral tissues. British Journal of Oral and Maxillofacial Surgery. 44:116-123.
92. MacPhail LA, Greenspan D, Feigal DW, Lennette ET, Greenspan JS. (1991). Recurrent aphthous ulcers in association with HIV infection. Description of ulcer types and analysis of T-lymphocyte subsets. Oral Surgery, Oral Medicine, Oral Pathology. 71:678-683.
93. MacPhail LA, Greenspan D, Greenspan JS. (1992). Recurrent aphthous ulcers in association with HIV infection. Diagnosis and treatment. Oral Surgery, Oral Medicine, Oral Pathology. 73:283-288.
94. Manfredi R, Mazzoni A, Nanetti A, Chiodo F. (1994). Histoplasmosis capsulati and duboisii in Europe: the impact of the HIV pandemic, travel and immigration. European Journal of Epidemiology. 10:675-681.
95. Marino D. (1995). HIV inhibitor identified in saliva. Dentistry Today. 14:22, 26-27.
96. Martins MD, Lozano-Chiu M, Rex JH. (1998). Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clinical Infectious Diseases. 27:1291-1294.
97. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. (1995). Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. Journal of Clinical Investigation. 96:456-464.
98. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. (1997). Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood. 90:1141-1149.
99. Miller CS, Avdiushko SA, Kryscio RJ, Danaher RJ, Jacob RJ. (2005). Effect of prophylactic valacyclovir on the presence of human herpesvirus DNA in saliva of healthy individuals after dental treatment. Journal of Clinical Microbiology. 43:2173-2180.
100. Miller CS, Berger JR, Mootoor Y, Avdiushko SA, Zhu H, Kryscio RJ. (2006). High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. Journal of Clinical Microbiology. 44:2409-2415.
101. Miziara ID, Weber R. (2006). Oral candidosis and oral hairy leukoplakia as predictors of HAART failure in Brazilian HIV-infected patients. Oral Diseases. 12:402-407.
102. Moore BE, Flaitz CM, Coppenhaver DH, Nichols M, Kalmaz GD, Bessman JD, Cloyd MW, Lynch DP, Prabhakar BS, Baron S. (1993). HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation. The Journal of the American Dental Association. 124:67-74.
103. Moore JS, Hall SD, Jackson S. (2002). Cell-associated HIV-1 infection of salivary gland epithelial cell lines. Virology. 297:89-97.
104. Moore JS, Rahemtulla F, Kent LW, Hall SD, Ikizler MR, Wright PF, Nguyen HH, Jackson S. (2003). Oral epithelial cells are susceptible to cell-free and cell-associated HIV-1 infection in vitro. Virology. 313:343-353.
105. Nacher M, Sarazin F, El Gruedj M, Vaz T, Alvarez F, Nasser V, Randrianjohany A, Aznar C, Carme B, Couppie P. (2006). Increased incidence of disseminated histoplasmosis following highly active antiretroviral therapy initiation. Journal of Acquired Immune Deficiency Syndromes. 41:468-470.
106. Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein LT, Malamud D. (1997). Human submandibular saliva specifically inhibits HIV type 1. AIDS Research and Human Retroviruses. 13:371-376.
107. Navazesh M, Barron Y, Greenspan D, Alves M, Phelan J. (2002). The relationship, among HAART, HIV disease markers, and salivary gland hypofunction. IADR/AADR/CADR 80th General Session (March 6-9, 2002).
108. Navazesh M, Mulligan R, Barron Y, Redford M, Greenspan D, Alves M, Phelan J. (2003). A 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women's Interagency HIV Study participants. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, Endodontology. 95:693-698.
109. Navazesh M, Mulligan R, Pogoda J, Greenspan D, Alves M, Phelan J, Greenspan J, Slots J. (2005). The effect of HAART on salivary microbiota in the Women's Interagency HIV Study (WIHS). Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 100:701-708.
110. Nicolatou-Galitis O, Velegraki A, Paikos S, Economopoulou P, Stefaniotis T, Papanikolaou IS, Kordossis T. (2004). Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Diseases. 10:145-150.
111. Nisapakultorn K, Ross KF, Herzberg MC. (2001). Calprotectin expression in vitro by oral epithelial cells confers resistance to infection by Porphyromonas gingivalis. Infection and Immunity. 69:4242-4247.
112. Nisapakultorn K, Ross KF, Herzberg MC. (2001). Calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infection and Immunity. 69:3692-3696.
113. Ogundele MO, Coulter JB. (2003). HIV transmission through breastfeeding: problems and prevention. Annals of Tropical Paediatrics. 23:91-106.
114. Ohlsson S, Falk R, Yang JJ, Ohlsson K, Segelmark M, Wieslander J. (2003). Increased expression of the secretory leukocyte proteinase inhibitor in Wegener's granulomatosis. Clinical and Experimental Immunology. 131:190-196.
115. Palms C, Serbousek D, Torosantucci A, Cassone A, Djeu JY. (1992). Identification of a mannoprotein fraction from Candida albicans that enhances human polymorphonuclear leukocyte (PMNL) functions and stimulates lactoferrin in PMNL inhibition of candidal growth. The Journal of Infectious Diseases. 166:1103-1112.
116. Piketty C, Kazatchkine MD. (2005). Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Current HIV/AIDS Reports. 2:140-145.
117. Pollock JJ, Santarpia RP, 3rd, Heller HM, Xu L, Lal K, Fuhrer J, Kaufman HW, Steigbigel RT. (1992). Determination of salivary anticandidal activities in healthy adults and patients with AIDS: a pilot study. Journal of Acquired Immune Deficiency Syndromes. 5:610-618.
118. Porter S. (2006). US8 Xerostomia. Oral Diseases. 12:4.
119. Posavad CM, Wald A, Kuntz S, Huang ML, Selke S, Krantz E, Corey L. (2004). Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. The Journal of Infectious Diseases. 190:693-696.
120. Pourtois M, Binet C, Van Tieghem N, Courtois P, Vandenabbeele: A, Thiry L. (1990). Inhibition of HIV infectivity by lactoperoxidase-produced hypothiocyanite. Journal of Biological Buccale. 18:251-253.
121. Powderly WG, Robinson K, Keath EJ. (1992). Molecular typing of Candida albicans isolated from oral lesions of HIV-infected individuals. AIDS. 6:81-84.
122. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, Medvik K, Sieg SF, Weinberg A. (2003). Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 17:F39-48.
123. Qureshi MN, Barr CE, Seshamma T, Reidy J, Pomerantz RJ, Bagasra O. (1995). Infection of oral mucosal cells by human immunodeficiency virus type 1 in seropositive persons. The Journal of Infectious Diseases. 171:190-193.
124. Ramos-Gomez F. (2002). Dental considerations for the paediatric AIDS/HIV patient. Oral Diseases. 8(Suppl 2):49-54.
125. Ranganathan K, Remalatha R. (2006). Oral lesions in HIV infection in developing countries: an overview. Advances in Dental Research. 19:63-68.
126. Reibel J, Dabelsteen E, Kenrad B, Buschard K. (1985). Pattern of distribution of T lymphocytes, Langerhans cells and HLA-DR bearing cells in normal human oral mucosa. Scandanivian Journal of Dental Research. 93:513-521.
127. Reichart P. (2006). US1 HIV - changing patterns in HAART era, patients' quality of life and occupational risks. Oral Diseases. 12(Suppl 1):3.
128. Renwick N, Halaby T, Weverling GJ, Dukers NH, Simpson GR, Coutinho RA, Lange JM, Schulz TF, Goudsmit J. (1998). Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS. 12:2481-2488.
129. Robinovitch MR, Iversen JM, Resnick L. (1993). Anti-infectivity activity of human salivary secretions toward human immunodeficiency virus. Critical Reviews in Oral Biology and Medicine. 4:455-459.
130. Rothenberg RB, Scarlett M, del Rio C, Reznik D, O'Daniels C. (1998). Oral transmission of HIV. AIDS. 12:2095-2105.
131. Samaranayake YH, Samaranayake LP, Pow EH, Beena VT, Yeung KW. (2001). Antifungal effects of lysozyme and lactoferrin against genetically similar, sequential Candida albicans isolates from a human immunodeficiency virus-infected southern Chinese cohort. Journal of Clinical Microbiology. 39:3296-3302.
132. Samuel MC, Hessol N, Shiboski S, Engel RR, Speed TP, Winkelstein W, Jr. (1993). Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984-1989. Journal of Acquired Immune Deficiency Syndromes. 6:303-312.
133. Schiodt M, Pindborg JJ. (1987). AIDS and the oral cavity. Epidemiology and clinical oral manifestations of human immune deficiency virus infection: a review. International Journal of Oral and Maxillofacial Surgery. 16:1-14.
134. Schmidt-Westhausen A, Grunewald T, Reichart PA, Pohle HD. (1997). Oral manifestations in 70 German HIV-infected women. Oral Diseases. 3(Suppl 1):S28-30.
135. Schwarcz SK, Kellogg TA, Kohn RP, Katz MH, Lemp GF, Bolan GA. (1995). Temporal trends in human immunodeficiency virus seroprevalence and sexual behavior at the San Francisco municipal sexually transmitted disease clinic, 1989-1992. American Journal of Epidemiology. 142:314-22.
136. Semba RD, Kumwenda N, Hoover DR, Taha TE, Quinn TC, Mtimavalye L, Biggar RJ, Broadhead R, Miotti PG, Sokoll LJ, van der Hoeven L, Chiphangwi JD. (1999). Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1. The Journal of Infectious Diseases. 180:93-98.
137. Shaheen F, Sison AV, McIntosh L, Mukhtar M, Pomerantz RJ. (1999). Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. Journal of Human Virology. 2:154-166.
138. Shiboski CH, Hilton JF, Greenspan D, Westenhouse JL, Derish P, Vranizan K, Lifson AR, Canchola A, Katz MH, Cohen JB, and et al. (1994). HIV-related oral manifestations in two cohorts of women in San Francisco. Journal of Acquired Immune Deficiency Syndromes. 7:964-971.
139. Shine N, Konopka K, Duzgunes N. (1997). The anti-HIV-1 activity associated with saliva. Journal of Dental Research. 76:634-640.
140. Shugars DC. (1999). Endogenous mucosal antiviral factors of the oral cavity. The Journal of Infectious Diseases. 179(Suppl 3):S431-435.
141. Shugars DC, Patton LL, Freel SA, Gray LR, Vollmer RT, Eron JJ, Jr., Fiscus SA. (2001). Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva. Journal of Dental Research. 80:414-420.
142. Shugars DC, Sauls DL, Weinberg JB. (1997). Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and manonuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Oral Diseases. 3(Suppl 1):S70-72.
143. Shugars DC, Slade GD, Patton LL, Fiscus SA. (2000). Oral and systemic factors associated with increased levels of human immunodeficiency virus type 1 RNA in saliva. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, Endodontology. 89:432-440.
144. Shugars DC, Sweet SP, Malamud, D, Kazmi SH, Page-Shafer K, Challacombe SJ. (2002). Saliva and inhibition of HIV-1 infection: molecular mechanisms. Oral Diseases. 8(Suppl 2):169-175.
145. Shugars DC, Wahl SM. (1998). The role of the oral environment in HIV-1 transmission. The Journal ofthe American Dental Association. 129:851-858.
146. Siegel RD, Granich R. (1993). Recurrent aphthous ulcers in association with HIV infection. Oral Surgery, Oral Medicine, Oral Pathology. 76:406-407.
147. Silverman S, Jr. (1987). Infectious disease control and the dental office: AIDS and other transmissible diseases. International Dental Journal 37:108-113.
148. Skott P, Lucht E, Ehnlund M, Bjorling E. (2002). Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism. Oral Diseases. 8:160-167.
149. Spear GT, Alves ME, Cohen MH, Bremer J, Landay AL. (2005). Relationship of HIV RNA and cytokines in saliva from HIV-infected individuals. FEMS Immunology and Medical Microbiology. 45:129-136.
150. Stahl-Hennig C, Steinman RM, Tenner-Racz K, Pope M, Stolte N, Matz-Rensing K, Grobschupff G, Raschdorff B, Hunsmann G, Racz P. (1999). Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science. 285:1261-1265.
151. Stapleton JT, Klinzman D, Wuenschmann S, Mccray P, Tack B. (1999). Anti-HIV Activity of Cathelicidins: Oxygen-Independent Antimicrobial Peptides Found in die Secondary granules of phagocytes. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 319 (abstract no. 935).
152. Sugawara S, Uehara A, Tamai R, Takada H. (2002). Innate immune responses in oral mucosa. Journal of Endotoxin Research. 8:465-468.
153. Syrjanen S. (2006). PL7 Oral viral infections that could be transmitted orogenitally. Oral Diseases. 12(Suppl 1):2.
154. Tawfik OW, Papasian CJ, Dixon AY, Potter LM. (1989). Saccharomyces cerevisiae pneumonia in a patient with acquired immune deficiency syndrome. Journal of Clinical Microbiology. 27:1689-1691.
155. Tenovuo J. (2002). Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety. Oral Diseases. 8:23-29.
156. Tenovuo J, Makinen KK, Sievers G. (1985). Antibacterial effect of lactoper-oxidase and myeloperoxidase against. Bacillus cereus. Antimicrobial Agents and Chemotherapy. 27:96-101.
157. Turpin JA, Schaeffer CA, Bu M, Graham L, Buckheit RW, Jr., Clanton D, Rice WG. (1996). Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leakocyte protease inhibitor. Antiviral Research. 29:269-277.
158. Tylenda CA, Larsen J, Yeh CK, Lane HC, Fox PC. (1989). High levels of oral yeasts in early HIV-1 infection. Journal of Oral Pathology and Medicine. 18:520-524.
159. Umadevi M, Adeyemi O, Patel M, Reichart PA, Robinson PG. (2006). (B2) Periodontal diseases and other bacterial infections. Advances in Dental Research. 19:139-145.
160. van't Hof W, Reijnders IM, Helmerhorst EJ, Walgreen-Weterings E, Simoons-Smit IM, Veerman EC, Amerongen AV. (2000). Synergistic effects of low doses of histatin 5 and its analogues on amphotericin B anti-mycotic activity. Antonie Van Leeuwenhoek. 78:163-169.
161. van Loon LA, Krieg SR, Davidson CL, Bos JD. (1989). Quantification and distribution of lymphocyte subsets and Langerhans cells in normal human oral mucosa and skin. Journal of Oral Pathology and Medicine. 18:197-201.
162. Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. (1999). Sexual transmission of HIV: infectiousness and prevention. AIDS. 13:155-166.
163. Vittinghoff E, Douglas J, Judson F, McKiman D, MacQueen K, Buchbinder SP. (1999). Per-contact risk of human immunodeficiency virus transmission between male sexual partners. American Journal of Epidemiology. 150:306-311.
164. Volter C, He Y, Delius H, Roy-Burman A, Greenspan JS, Greenspan D, de Villiers EM. (1996). Novel HPV types present in oral papillomatous lesions from patients with HIV infection. International Journal of Cancer. 66:453-456.
165. Vucicevic-Boras V, Brozovic S, Cekic-Arambasin A, Zadro R, Devcic T, Begovac J, Brailo V. (2003). Salivary peroxidase levels in patients with AIDS. European Journal of Medical Research. 8:81-84.
166. Wahl SM, McNeely TB, Janoff EN, Shugars D, Worley P, Tucker C, Orenstein JM. (1997). Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Diseases. 3(Suppl 1):S64-69.
167. Wahl SM, Worley P, Jin W, McNeely TB, Eisenberg S, Fasching C, Orenstein JM, Janoff EN. (1997). Anatomic dissociation between HIV-1 and its endogenous inhibitor in mucosal tissues. American Journal of Pathology. 150:1275-1284.
168. Wanzala P, Manji F, Pindborg JJ, Plummer F. (1989). Low prevalence of oral mucosal lesions in HIV-1 seropositive African women. Journal of Oral Pathology and Medicine. 18:416-418.
169. Webster-Cyriaque J, Duns K, Cooper C, Duncan M. (2006). Oral EBV and KSHV infection in HIV. Advances in Dental Research. 19:91-95.
170. Wei GX, Bobek LA. (2005). Human salivary mucin MUC7 12-mer-L and 12-mer-D peptides: antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, cytotoxicity to human cells. Antimicrobial Agents and Chemotherapy. 49:2336-2342.
171. Weinberg A, Quinones-Mateu ME, Lederman MM. (2006). Role of human beta-defensins in HIV infection. Advances in Dental Research. 19:42-48.
172. Widmer IC, Erb P, Grob H, Itin P, Baumann M, Stalder A, Weber R, Cathomas G. (2006). Human herpesvirus 8 oral shedding in HIV-infected. men with and without Kaposi sarcoma. Journal of Acquired Immune Deficiency Syndrom es. 42:420-425.
173. Wofsy CB, Cohen JB, Hauer LB, Padian NS, Michaelis BA, Evans LA, Levy JA. (1986). Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet. 1:527-529.
174. Wu X, Hall S, Jackson S. (2003). Tropism-restricted neutralization by secretory IgA from parotid saliva of HIV type 1-infected individuals. AIDS Research and Human Retroviruses. 19:275-281.
175. Wit Z, Van Ryk D, Davis C, Abrams WR, Chaiken I, Magnani J, Malamud D. (2003). Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Research and Human Retroviruses. 19:201-209.
176. Xie H, Belogortseva NI, Wu J, Lai WH, Chen CH. (2006). Inhibition of human immunodeficiency virus type 1 entry by a binding domain of Porphyromonas gingivalis gingipain. Antimicrobial Agents and Chemotherapy. 50:3070-3074.
177. Yapijakis C, Panis V, Koufaliotis N, Yfanti G, Karachalios S, Roumeliotou A, Mantzavinos Z. (2006). Immunological and molecular detection of human immunodeficiency virus in saliva, comparison with blood testing. European Journal of Oral Sciences. 114:175-179.
178. Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR, 3rd. (2006). Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Archives of Pediatrics and Adolescent Medicine. 160:778-787.
179. Zanetti M, Gennaro R, Romeo D. (1995). Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Letters. 374:1-5.
180. Zhang H, Dornadula G, Pomerantz RJ. (1998). Natural endogenous reverse transcription of HIV-1. Journal of Reproductive Immunology. 41:255-260.
181. Zheng J, Yang OO, Xie Y, Campbell R, Chen IS, Pang S.(2004). Ethanol stimulation of HIV infection of oral epithelial cells. Journal of Acquired Immune Deficiency Syndromes. 37:1445-1453.
182. Zuckerman RA, Whittington WL, Celum CL, Collis T, Lucchetti A, Sanchez JL, Hughes JP, Coombs RW. (2003). Factors associated with oropharyngeal human immunodeficiency virus shedding. The Journal of Infectious Diseases. 188:142-145.